Seeking alpha in PI3K inhibition
Novartis hails the most advanced alpha-directed PI3K inhibitor after success in breast cancer, but it’s not the only one.
Aveo comeback highlights a transatlantic split
Most drugs get the nod in the US before Europe – but there are some cases where the usual trend is reversed.
Aveo comeback highlights a transatlantic split
After the recent EU positive opinion for Aveo's tivozanib, EP Vantage takes a look at other projects approved in the EU, but not the US.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.